HK Stock Market Move | VIVA BIOTECH (01873) rose more than 18% in the last trading session, driven by AI-enhanced research and development efficiency and the construction of an investment incubation ecosystem.

VIVA BIOTECH (01873) surged by over 18% in the final trading session, as of the time of writing, it rose by 18.09% to 2.35 Hong Kong dollars, with a trading volume of 64.7058 million Hong Kong dollars. On the news front, VIVA BIOTECH's public account recently disclosed that on January 13, during the 44th J.P. Morgan Healthcare Conference, the company successfully held the Viva Biotech Innovation Forum 2026. The forum deeply discussed the cutting-edge progress of artificial intelligence and new types of drugs. In particular, VIVA BIOTECH shared about the AI-enabled full process experimental design of peptide drug development and the AI-enabled peptide CRDMO platform, highlighting how artificial intelligence accelerates the landing of key links in research and industrialization, becoming a key focus of the conference. Zheshang previously pointed out that looking ahead, with the continuous increase in the proportion of AI application projects in the CRO sector and the gradual landing of major commercial projects in CDMO, the bank is optimistic about the company's trend of high profitability. Guosheng believes that overall, the company is expected to continue to benefit from the synergy development of CRO and CDMO, the effectiveness improvement of AI-driven research and the construction of investment and incubation ecosystem, driving steady growth in performance and long-term value release in the global innovative drug industry.